Expanded Indication

NOW APPROVED IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH UNCONTROLLED MODERATE‑TO‑SEVERE ATOPIC DERMATITIS

When topical Rx therapies are not enough, DUPIXENT may be appropriate

Patients 6+ months of age may be appropriate for DUPIXENT if they:

  • Have tried a variety of topical prescription therapies for moderate-to-severe atopic dermatitis and are still uncontrolled1
  • Suffer from inadequate control of pruritus1
  • Have ≥10% of their body covered with lesions and/or may involve
    problem areas, such as the face, hands, and feet1
  • Have moderate-to-severe erythema and moderate-to-severe
    papulation/infiltration (IGA 3 or 4)1,2

Learn more about identifying appropriate patients to refer.

For your appropriate patients trapped in “flare then treat” cycles, consider referring to a DERMATOLOGIST or ALLERGIST

Use the Healthgrades® tool to find and partner with a nearby eczema specialist - one with experience
treating uncontrolled moderate-to-severe atopic dermatitis in patients aged 6+ month of age.

Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.

DUPIXENT specifically targets a source of underlying inflammation to proactively treat atopic dermatitis1,3

Atopic dermatitis is a chronic, systemic disease driven in part by persistent underlying type 2 inflammation4

  • Even when patients are not in a flare, they continue to
    have underlying inflammation3
  • Systemic treatment may be needed to help manage
    uncontrolled moderate-to-severe atopic dermatitis1,5

The mechanism of dupilumab action has not been definitively established.

DUPIXENT Is Revolutionizing Atopic Dermatitis
DUPIXENT has proven itch relief and skin
clearance in patients 6+ months of age with
uncontrolled moderate-to-severe atopic dermatitis1

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis,
oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients
through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of
DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with
hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not
study lead to drug discontinuation.1

TRIAL DESIGNS AND RESULTS

Other attributes of DUPIXENT

DUPIXENT is not an
immunosuppressant
or a steroid1

No requirement for initial lab testing or ongoing lab monitoring according to the Prescribing Information1

One dose every 2 or 4 weeks based on age and weight (after an initial loading dose of two subcutaneous injections) in patients aged 6+ years. For patients aged 6 months to 5 years, one dose every 4 weeks based on weight, with no initial loading dose recommended.1

Extensive real-world experience1,3

≈253,000 patients have filled at least 1 DUPIXENT prescription2,a,b
5 years on the market since initial FDA approval in ADc

aIQVIA National Source of Business (NSOB) data as of April 2022.

bNew adult and pediatric patients (6+ years of age) with uncontrolled moderate-to-severe atopic dermatitis.

cFDA approved since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years),
and 2022 for infants to preschoolers (aged 6 months to 5 years) with uncontrolled moderate-to-severe atopic dermatitis.

Expanded Indication

NOW APPROVED IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH UNCONTROLLED MODERATE‑TO‑SEVERE ATOPIC DERMATITIS

Questions about DUPIXENT?

Below are the answers to some of the most frequently asked questions about DUPIXENT.

DUPIXENT MyWay® provides eligible patients with support

We're committed to helping ensure patients have access to DUPIXENT and are provided with assistance in navigating the insurance process.

  • 99% of commercial patients nationally are covered for DUPIXENT, with 83% of patient lives having to fail only 1 or 2 prescription topical treatments, and 76% of children ages 6 to 11 years having to fail only 1 or 2 topical treatments.2,a

aMMIT Analysis, August 2022.